DNA and glutathione interactions in cell-free media of asymmetric platinum(II) complexes cis- and trans-[PtCl2(isopropylamine)(1-methylimidazole)]: relations to their different antitumor effects.
The global modification of mammalian and plasmid DNAs by the novel platinum compounds cis-[PtCl(2)(isopropylamine)(1-methylimidazole)] and trans-[PtCl(2)(isopropylamine)(1-methylimidazole)] and the reactivity of these compounds with reduced glutathione (GSH) were investigated in cell-free media using various biochemical and biophysical methods. Earlier cytotoxicity studies had revealed that the replacement of the NH(3) groups in cisplatin by the azole and isopropylamine ligands lowers the activity of cisplatin in both sensitive and resistant cell lines. The results of the present work show that this replacement does not considerably affect the DNA modifications by this drug, recognition of these modifications by HMGB1 protein, their repair, and reactivity of the platinum complex with GSH. These results were interpreted to mean that the reduced activity of this analog of cisplatin in tumor cell lines is due to factors that do not operate at the level of the target DNA. In contrast, earlier studies had shown that the replacement of the NH(3) groups in the clinically ineffective trans isomer (transplatin) by the azole and isopropylamine ligands results in a radical enhancement of its activity in tumor cell lines. Importantly, this replacement also markedly alters the DNA binding mode of transplatin, which is distinctly different from that of cisplatin, but does not affect reactivity with GSH. Hence, the results of the present work are consistent with the view and support the hypothesis systematically tested by us and others that platinum drugs that bind to DNA in a fundamentally different manner from that of conventional cisplatin may have altered pharmacological properties.
Suchánková
Tereza
T
Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, 61265, Brno, Czech Republic.
Vojtísková
Marie
M
Reedijk
Jan
J
Brabec
Viktor
V
Kaspárková
Jana
J
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D002474:Cell-Free System; D002942:Circular Dichroism; D003470:Culture Media / Q000737:chemistry*; D004247:DNA / Q000737:chemistry* / Q000187:drug effects; D005978:Glutathione / Q000737:chemistry* / Q000187:drug effects; D006801:Humans; D009944:Organoplatinum Compounds / Q000737:chemistry* / Q000494:pharmacology; D013056:Spectrophotometry, Ultraviolet; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D003470:Culture Media; D009944:Organoplatinum Compounds; C541499:dichloro(isopropylamine)(1-methylimidazole)diplatinum(II); D004247:DNA; D005978:Glutathione
Cancer Res. 1992 Sep 15;52(18):5065-72
1516063
Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
11525387
Biophys Chem. 1996 Jun 11;60(3):135-42
8679924
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9
8506383
Nature. 1999 Jun 17;399(6737):708-12
10385126
Drug Resist Updat. 2005 Jun;8(3):131-46
15894512
Eur J Biochem. 1997 Jun 1;246(2):508-17
9208945
Biochemistry. 1985 Jan 29;24(3):707-13
4039603
Anticancer Agents Med Chem. 2007 Jan;7(1):111-23
17266508
Mol Pharmacol. 2006 Nov;70(5):1708-19
16896071
FEBS Lett. 1994 May 16;344(2-3):201-6
8187884
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982-5
2000402
Carcinogenesis. 1989 Dec;10(12):2367-9
2591026
Prog Nucleic Acid Res Mol Biol. 2002;71:1-68
12102553
Biophys Chem. 1990 Apr;35(2-3):129-41
2204440
Biochemistry. 1996 Mar 5;35(9):2992-3000
8608137
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20743-8
18093923
Mutat Res. 2001 Jul 1;478(1-2):1-21
11406166
Science. 1992 Apr 10;256(5054):234-7
1566071
Pharmacol Ther. 1987;34(2):155-66
3317449
Drug Metab Dispos. 2003 Jul;31(7):916-23
12814969
Cancer Res. 1999 Aug 15;59(16):3968-71
10463593
Proc Natl Acad Sci U S A. 1980 Jul;77(7):3855-9
6933441
Science. 1979 Mar 9;203(4384):1014-6
370979
Nucleic Acids Res. 1985 Apr 25;13(8):2881-95
4039817
Biochemistry. 1987 Jun 16;26(12):3303-7
3651385
J Inorg Biochem. 2006 Dec;100(12):1955-64
17083978
Biochemistry. 2003 May 27;42(20):6321-32
12755637
Anticancer Drug Des. 1986 Apr;1(2):95-109
3450293
J Biol Inorg Chem. 2005 Nov;10(7):722-31
16208494
Anticancer Agents Med Chem. 2007 Jan;7(1):19-34
17266503
J Med Chem. 2006 Apr 20;49(8):2640-51
16610807
Chem Rev. 1999 Sep 8;99(9):2499-510
11749488
J Biol Chem. 2002 Dec 13;277(50):48076-86
12226099
Drug Resist Updat. 1998;1(4):243-54
16904407
J Biol Chem. 1992 Jul 5;267(19):13520-7
1618852
Drug Resist Updat. 2002 Jul-Aug;5(3-4):147-61
12237082
Crit Rev Oncol Hematol. 2000 Aug;35(2):109-20
10936468